|
Genotype
|
Placebo
| |
ET
| |
EPT
| | |
|---|
| |
Mean (N)
|
SEM
|
P*
|
Mean (N)
|
SEM
|
P
|
Mean (N)
|
SEM
|
P
|
P
†
|
|---|
|
COMT Val158Met
| | | | | | | | | | |
|
Val/Val
|
- 0.1 (30)
|
1.4
|
Ref.
|
3.7 (30)
|
1.4
|
Ref.
|
8.0 (12)
|
2.3
|
Ref.
| |
|
Val/Met
|
0.5 (45)
|
1.2
|
0.74
|
4.3 (48)
|
1.1
|
0.72
|
6.2 (19)
|
1.9
|
0.54
| |
|
Met/Met
|
- 0.6 (19)
|
1.8
|
0.82
|
6.0 (25)
|
1.6
|
0.27
|
9.8 (3)
|
4.5
|
0.72
|
0.77
|
|
CYP1B1 Val432Leu
| | | | | | | | | | |
|
Val/Val
|
- 0.7 (15)
|
1.9
|
Ref.
|
4.7 (23)
|
1.6
|
Ref.
|
6.9 (7)
|
2.9
|
Ref.
| |
|
Leu/Val
|
- 0.01 (42)
|
1.2
|
0.75
|
5.8 (44)
|
1.2
|
0.57
|
1.3 (13)
|
2.1
|
0.11
| |
|
Leu/Leu
|
0.9 (36)
|
1.2
|
0.47
|
3.6 (37)
|
1.2
|
0.61
|
14.5 (13)
|
2.1
|
0.03
|
0.0004
|
|
UGT1A1
| | | | | | | | | | |
|
<7/<7 TA repeats
|
0.3 (37)
|
1.3
|
Ref.
|
5.7 (50)
|
1.1
|
Ref.
|
7.1 (18)
|
1.9
|
Ref.
| |
|
<7/≥ 7 TA repeats
|
- 0.5 (43)
|
1.2
|
0.60
|
3.3 (39)
|
1.3
|
0.15
|
8.7 (12)
|
2.3
|
0.57
| |
|
≥ 7/≥ 7 TA repeats
|
0.6 (14)
|
2.1
|
0.92
|
4.4 (14)
|
2.1
|
0.58
|
5.4(3)
|
4.6
|
0.74
|
0.77
|
|
AKR1C4 L311V
| | | | | | | | | | |
|
Leu/Leu
|
- 0.3 (72)
|
0.9
|
Ref.
|
4.3 (79)
|
0.8
|
Ref.
|
4.0 (25)
|
1.6
|
Ref.
| |
|
Leu/Val
|
1.5 (21)
|
1.6
|
0.30
|
5.5 (25)
|
1.5
|
0.47
|
16.7 (7)
|
2.8
|
0.0001
| |
|
Val/Val
|
0.6 (1)
| |
0.90
|
(0)
| | |
29.3 (1)
| |
0.0007
|
0.001
|
- Figures are adjusted for race, age at baseline, years since menopause, body mass index (BMI) at baseline, change in BMI on trial, mammographic percentage density at baseline, past use of hormone therapy and study group.
- *Analysis of covariance P for comparison of means; †analysis of covariance P for ET/EPT × genotype interaction. AKR1C4, aldo-keto reductase 1C4; COMT, catechol-O-methyltransferase; CYP1B1, cytochrome P450 1B1; EPT, estrogen and progestin therapy; ET, estrogen therapy; UGT1A1, UDP-glucuronosyltransferase 1A1.
